Kornimate/medical-research-clean huggingface dataset:
comparison of analgesic effect of magnesium added to ropivacaine and ropivacaine alone in caudal analgesia on postoperative pain control in pediatric patients undergoing inguinal hernia repair

Conditions: Inguinal Hernia

Summary: a caudal anesthesia is one of the most commonly used technique providing intra and postoperative analgesia in pediatric low abdominal surgery. the practice of adding adjunct analgesic drugs to local anesthetics for caudal block is common. the most commonly used drugs are opioids, clonidine, and ketamine. however, their use has been limited by adverse effects in children. recently, the importance of magnesium in analgesic effects has been increased. magnesium is the fourth most abundant cation in the body. it has antinociceptive effects in human and these effects are primarily based on the regulation of calcium influx into the cell. magnesium is a physiological calcium antagonist and blocks n-methyl-d-aspartate (nmda) receptor and such nmda antagonism prevents the central sensitization from nociceptive stimulation. many study suggested that epidurally administered magnesium could reduce the postoperative pain in adults. but few studies are available about the use of magnesium in pediatrics. the investigators performed prospective randomized double-blind study to examine the analgesic effect of magnesium added to ropivacaine and ropivacaine alone in caudal analgesia on postoperative pain control in pediatric patients undergoing inguinal hernia repair. 80 children (aged 2- 6 yr) undergoing inguinal hernia repair were included in this prospective, randomized, double-blinded study. after inhalation induction of general anesthesia, caudal block was applied. patients were randomly assigned in two groups. normal saline 0.5ml added to ropivacaine 0.15% 1.0 ml/kg was administered to group r , magnesium 50mg (magnesium 10% 0.5ml)added to ropivacaine 0.15% 1.0ml/kg to group mr. postoperative pain was recorded at 30min and 1,2,3 h by using hospital of eastern ontario pain scale (cheops, 0-10) and faces legs activity cry consolability tool (flacc, 0-10). participants will be followed for the duration of hospital stay, an expected average of 3 hours. after discharge, rescue analgesic consumption, pain scores (parents postoperative pain measurement, pppm), and adverse effects were evaluated for 48h. the time to first supplemental oral analgesic medication demand was defined as the time from the end of surgery to the first registration of a pppm( 0 - 15) ≥ 6 by parent's observation. 48 hours after surgery, reports of delayed side effects and demands for rescue analgesics from the child were gathered from parents via a telephone interview.


Eligibility criteria:
inclusion criteria: * asa status i-ii, * children aged 2 to 6 yr * weight under 20kg * undergoing inguinal hernia repair exclusion criteria: * hypersensitivity fo any local anesthetics, * bleeding diathesis, infections at puncture sites, * pre-existing neurological disease, * patients taking calcium channel block, * patients taking opioid

Keywords: inguinal hernia, caudal analgesia, magnesium
social isolation but not deprivation involved in employment status after bariatric surgery.

Conditions: Bariatric Surgery; Weight Loss; Employment; Obesity

Summary: this study looked at how bariatric surgery (weight-loss surgery) affects people's chances of getting a job, especially in a low-income area. researchers followed 133 patients (mostly women, average age 45) about 2 years after their surgery. most had a type of surgery called sleeve gastrectomy and lost a significant amount of weight. they found that 19 people got a job after surgery, but 3 also became unemployed. people who were already employed before surgery had better results on satisfaction and well-being scores. interestingly, finding a new job after surgery wasn't linked to weight loss, age, or sex. also, being poor (measured by the epices score) didn't affect employment outcomes. however, people who felt more socially isolated were less likely to lose weight successfully.


Eligibility criteria:
inclusion criteria: * patients who underwent bariatric surgery (mainly sleeve gastrectomy). * follow-up duration of approximately 2.3 ± 0.1 years after surgery. * residing in a deprived area (context of the study). * adults (participants were aged between 18 and 67 years). exclusion criteria: * patients who did not undergo bariatric surgery. * missing or incomplete data (e.g., unanswered questionnaires). * patients outside the follow-up period (less or more than 2.3 years post-surgery). * possibly: minors (\<18 years old).
a real world study of anti-pd-1/pd-l1 antibodies for the treatment of advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the study was designed to analyze the efficacy and safety of anti-pd-1/pd-l1 antibodies for the treatment of advanced solid tumors.

the study is a real-world study and the case records of patients with advanced solid tumors who visited department of medical oncology, chinese pla general hospital from 2015 to 2019 and received anti-pd-1/pd-l1 antibody therapy will be collected in this study. the medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to analyze the effectivity and safety of anti-pd-1/pd-l1 antibodies and explore the prognosis-relevant factors of advanced solid tumors.

Eligibility criteria:
inclusion criteria: * pathologically or cytologically confirmed advanced solid tumors; * received anti-pd-1/pd-l1 antibody therapy. exclusion criteria: * no specific exclusion criteria in this real world study.

Keywords: anti-pd-1/pd-l1 antibodies efficacy safety real world study
prosthetic and biological complications of implant supported prostheses

Conditions: Implant Complication

Summary: complications of implant retained prostheses

counting and analyzing the prosthetic and biological complications of the fixed and removable implant retained prostheses in the completely edentulous patients

Eligibility criteria:
inclusion criteria: * completely edentulous patients exclusion criteria: * medically free adequate bone quality and quantity

Keywords: dental implant prosthesis completely edentulous
nilotinib for patients with chronic myeloid leukemia in first line and any subsequent line

Conditions: Chronic Myeloid Leukemia

Summary: this was a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for chronic myeloid leukemia patients treated with nilotinib.

the observation period per patient was 24 months. all patients were treated with nilotinib in accordance to the clinical routine at the respective institution and the summary of product characteristics (smpc). the observation intervals (documentation at baseline and at about 3, 6, 9, 12, 18 and 24 months) were not fixed and were aligned with the regular treatment schedule and the clinical symptoms of each patient. the medical decision about the schedule as well as therapeutic and diagnostic measures was made solely by the responsible physician. patients who discontinued treatment within two years of the observation period were followed until starting a new tki therapy line, however with a maximum time period of six months. all other patients that reached the official end of treatment after completion of the 24-month observation period were followed up for 28 days.

Eligibility criteria:
inclusion criteria: * adult patients diagnosed with ph+ cml (or evidence of bcr-abl transcript) treated with nilotinib under routine medical practice and the smpc, as amended, in first or any subsequent line, if the current therapy with nilotinib has not been in place for more than twelve months. retrospective documentation of patients for up to one year will be permitted. * patients who have already had an interruption/discontinuation of nilotinib therapy. * patients who have been informed about this nis and have personally dated and signed their informed consent form. exclusion criteria: * there are no exclusion criteria, apart from the contraindications mentioned in the smpc. participating patients are not allowed to take part in a clinical trial in parallel,

Keywords: chronic myeloid leukemia cml nofretete nilotinib
effect of nocturnal administration of anti-hypertensive medications in non-dippers

Conditions: Hypertension

Summary: the purpose of this study is to determine the effect of nocturnal administration of anti-hypertensive medications in non-dippers. efficacy variables. 1. echo 2. 24hr. horter 3. imt 4. bun/crea, urine analysis (microalbulinuria 5. cardio vascular event. "


Eligibility criteria:
inclusion criteria: 1. essential hypertension (stage 1-2) 2. 24hr. holer : non-dipper 3. age 18 \~70. exclusion criteria: 1. any known malignant disease 2. renal failure , creatinine \>2.0mg/dl 3. liver disease

Keywords: non-dipper htn patient
efficacy study of a cervical pessary containing progesterone for the prevention of preterm delivery

Conditions: Preterm Birth

Summary: assess the efficacy of 2 cervical pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34 (33 weeks and 6 days), when the pessary is inserted during weeks 16th and 24th and removed at 36 weeks and 6 days in pregnant women at high risk of premature birth.

participant selection will be performed by screening the general population of pregnant women with single fetus monitored by the hospital healthcare network, to investigate by serial transvaginal ultrasound performed between gestation weeks 16 (0 day to 7 days) and 24 (0 day to 7 days) those patients who have a cervical length between 10 mm and 25 mm, and/or women with a single fetus and cervical length ≥10 mm presenting one or more of the following risk factors: 1. preterm birth prior to 35 (34 weeks and 6 days) weeks of gestation; 2. premature rupture of membranes prior to 35 (34 and 6 days) weeks of gestation. after insertion of the pessary or beginning of the administration with vaginal progesterone capsules and until 28 weeks of gestation, participants in the 3 treatment groups will be monitored every 4 weeks at the most or more often, if the site has established so as a control standard. after 28 weeks, patients should be monitored every 2 weeks. the proportions of spontaneous preterm delivery before gestation weeks 32 and 34 will be compared between the control group and the 2 groups with the pessaries containing different doses of progesterone.

Eligibility criteria:
inclusion criteria: * women with a single pregnancy and a cervical length of 10 mm - 25 mm between 16 and 24 weeks of gestation, without any previous factors. * women with a single pregnancy with 10 mm or more cervical length between 16 and 24 weeks of gestation, and pre-existing risk factors risk factors for preterm birth: * previous preterm birth before week 35. * previous rupture of membranes before week 35 exclusion criteria: * pregnancies with: * major fetal abnormalities, such as lethal malformations or malformations requiring pre- or post-natal surgery; and fetal death before inclusion into the study. * history of rupture of membranes or prophylactic cerclage before study entry. * cervical or vaginal injuries prior to insertion of the pessary (e.g., cervical erosion secondary to trauma, infection, or carcinoma; vesicovaginal or rectovaginal fistulas). * unconscious, severely ill or mentally disabled patients, or under 16 years of age. * patients for whom use of progesterone is contraindicated. * patients with history of thrombosis.

Keywords: preterm birth short cervix cervical pessaries progesterone
atrial functional mitral regurgitation response in mitral loop cerclage annuloplasty (africa study)

Conditions: Atrial Functional Mitral Regurgitation; Heart Failure

Summary: to evaluate second stage safety and feasibility of mitral loop cerclage(mlc) annuloplasty with cstv for repair of functional mitral regurgitation.

the objective of this prospective, single-center, open label, feasibility test is to assess the safety and efficacy of mitral loop cerclage annuloplasty with cstv protective device, in treating functional mitral regurgitation (fmr) associated with heart failure and atrial fibrillation mitral regurgitation response in mitral loop cerclage annuloplasty.

Eligibility criteria:
inclusion criteria: * nyha(new york heart association) class iii - iv * and, functional mitral regurgitation 3+ (moderate/severe) or 4+ (severe) in spite of optimal medical treatment. (for optimal medical treatments, ①ace inhibitor or angiotensin receptor blocker ②β-blocker ③ aldosterone antagonists should be given for at least 3 months unless the subject has contraindication for each drug) * and, chronic atrial fibrillation in electrocardiography (persistent af or permanent af) exclusion criteria: * primary mitral regurgitation * lv ejection fraction lower than 30% * pulmonary arterial pressure ≥ 60mmhg * end-diastolic left ventricular dimension ≥ 70mm * subjects with functional mr who need cabg or avr performed * pre-existing stent in a coronary artery that is deemed to be in direct contact with the path of mitral loop cerclage along coronary sinus * subjects who have functional mr caused by aortic valve disease * subjects who have uncontrollable hyperthyroidism * subjects who have severe tr due to primary valve leaflet disease * anomaly of coronary sinus * pre-existing devices in coronary sinus such as implantable cardioverter defibrillator and pacemaker * 2:1 atriventricular av block or higher av block and ventricular tachycardia * subjects with primary mr * subjects who cannot be screened by cardiac ct * subjects who have possibility of coronary artery pinching even with mitral loop cerclage system judged by cardiac ct * subjects who do not have septal vein or have unsuitable septal vein anatomy by cardiac ct or venogram * subjects who have thrombosis and embolism * creatinine ≥2.0 mg/dl * subjects who have coagulation disorders * subjects who are unable to take anti-platelet agents * pre-existing devices such as implantable cardioverter defibrillator and pacemaker * subjects who are pregnant, or lactating, or plan pregnancy during the clinical trials * subjects who are participated in other clinical trials within 1 month of enrollment * subjects who are deemed not to be eligible in this study by physician's discretion

Keywords: percutaneous mitral valve repair coronary sinus annuloplasty mitral loop cerclage atrial fibrillation mitral regurgitation
evaluating the effect of surgical safety checklists on perioperative complications in children

Conditions: Intraoperative Complications; Postoperative Complications

Summary: the purpose of this study is to see if the surgical safety checklist is associated with a reduction in perioperative complications for children undergoing surgery in ontario, canada.


Eligibility criteria:
inclusion criteria: * surgical admission, with a noncardiac surgical interventions * aged between \>28 days and \<18years on the day of the surgical intervention exclusion criteria: * non-surgical admission * surgical interventions with \<10 per group * cardio-thoracic and interventional cardiology procedures

Keywords: surgical safety checklist perioperative complications pediatric
norfloxacin in the primary prophylaxis of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis; Hepatorenal Syndrome; Cirrhosis

Summary: advanced liver disease and low ascitic fluid protein concentration have been identified as risk factors for spontaneous bacterial peritonitis in cirrhosis. moreover, renal impairment and hyponatremia increase mortality rate of this infection. aims: to investigate if oral administration of norfloxacin prevents the first episode of sbp, hepatorenal syndrome and improves survival in cirrhotic patients with ascites and low protein concentration in ascitic fluid (\<15 g/l) and at least one of the following inclusion criteria: functional renal failure (serum creatinine ≥ 1,2 mg/dl or bun ≥ 25 mg/dl), hyponatremia (serum sodium ≤ 130 meq/l) or advanced liver disease (child ≥ 9 points with serum bilirubin ≥ 3 mg/dl). methods: prospective, multicenter, randomized, double-blind placebo controlled trial comparing oral norfloxacin (400 mg/d; n=35) with placebo (n=35).


Eligibility criteria:
inclusion criteria: * age 18-80 years, protein concentration in ascitic fluid \< 15 g/l and at least one of the following: serum creatinine ≥ 1.2 mg/dl or bun ≥ 25 mg/dl, serum sodium ≤ 130 meq/l or severe liver failure as defined by a child-pugh score ≥ 9 points and a serum bilirubin ≥ 3 mg/dl. exclusion criteria: * previous history of spontaneous bacterial peritonitis or of norfloxacin prophylaxis, allergy to quinolones, hepatocellular carcinoma, organic renal failure and hiv infection

Keywords: norfloxacin, primary prophylaxis, sbp
a study to investigate the safety and efficacy of teg002 in relapsed/refractory multiple myeloma patients

Conditions: Multiple Myeloma, Refractory; Multiple Myeloma in Relapse; Multiple Myeloma

Summary: this is a single arm, open-label, multicenter phase i study to assess the safety, tolerability and preliminary efficacy of autologous t cells transduced with a specific γδtcr, i.e. teg002, in a dose escalation and expansion study in relapsed/refractory multiple myeloma patients. the study will comprise of a dose escalation segment and an expansion segment. the study consists of a screening period, leukapheresis of mononuclear cells, and conditioning chemotherapy, followed by teg002. all subjects continue to be followed regularly for safety and efficacy assessments until 1 year after teg002 administration.


Eligibility criteria:
inclusion criteria: * signed informed consent * adult * relapsed or refractory multiple myeloma as defined by the imwg * life expectancy ≥3 months * ecog performance status 0 or 1 * adequate vital organ function * adequate bone marrow function * toxicities from prior/ongoing therapies recovered to ≤ grade 2 or subject's baseline * wcbp and men who can father children must be willing and able to use adequate contraception exclusion criteria: * any uncontrolled medical or psychiatric disorder that would preclude participation as outlined * pregnant or lactating women * amyloidosis * uncontrolled infection(s) * active cns disease * previous allogeneic-hsct * history of another primary malignancy that requires intervention beyond surveillance or that has not been in remission for at least 1 year. * subjects that received experimental or systemic therapy \< 14 days before teg002 infusion * nyha class ≥ ii * patients depending on dialysis * patients with a history of pulmonary embolism or deep vein thrombosis * t cell mediated active autoimmune disease or any active autoimmune disease requiring immunosuppressive therapy

Keywords: t cell therapy engineered t cells teg tegs teg002
efficacy and safety of jiedu tongluo granules for post-stroke depression

Conditions: Post-stroke Depression

Summary: to explore the efficacy and safety of jiedu tongluo granules for post stroke depression. a randomized, double-blind, placebo-controlled clinical trial was designed. the treatment group was administered the jiedu tongluo granules, while the control group was administered the placebo.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke, with neurological deficits symptoms; * clinical diagnosis of depression, according to the diagnostic and statistical manual of mental disorders-iv （dsm-iv）or chinese classification and diagnostic criteria of mental disorders-3(ccmd-3), the score is between 7 to 24 by 17-item hamilton depression; * age of 45 to 80 years old; * the patient is conscious, cooperation, without aphasia and severe cognitive impairment after acute phase of stroke; * without psychiatric disease history or family history of psychosis before stroke; * no hormones and psychotropic drugs were used within 1 month before enrollment; * capacity to provide written consent. exclusion criteria: * with brain organic disease such as brain tumors; * had a history of psychiatric illness or depression before stroke; * combined with severe liver, kidney, hematopoietic system disorder; * poor glycemic control and insulin-dependent diabetes; * participate in any clinical trial or taking antidepressant treatment 1 month prior to baseline; * pregnant or breast feeding; * history of sensitivity to chinese medicine ingredients.
laparoscopy-assisted and open distal gastrectomy for gastric cancer in the elderly patients

Conditions: Complications

Summary: * laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer (egc) has been supported by high-quality evidence, and the high-level evidence for advanced gastric cancer based on large prospective randomized controlled trial as class-01、jcog 0901, klass -02 is still awaited.hopefully, it would have also gained the solid evidence of laparoscopy-assisted distal gastrectomy for the treatment of advanced gastric cancer (agc). * china has entered the aging society since 1999. among the gc patients in china, the average age is 65 years old, which makes increasing attempts to explore laparoscopic techniques in the treatment of elderly patients. * nowadays, a considerable proportion of elderly patients suffer from multiple diseases, such as hypertension, diabetes, coronary heart disease. thus the risk of intraoperative and postoperative complications can not be ignored. unfortunately, there are rare studies specializing into the lag for the gc patients of \> 65 years old. * accordingly, the comparison of intraoperative and postoperative complications between laparoscopy-assisted and open distal gastrectomy for over 65 years old patients with gastric cancer based on a randomized controlled trial is warranted.


Eligibility criteria:
inclusion criteria: * age over 65 years * primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy * ct1-4a, n0-3, m0 at preoperative evaluation according to the ajcc cancer staging manual seventh edition * expected curative resection through distal subtotal gastrectomy with d2 lymphadenectomy * performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale * asa (american society of anesthesiology) score class i, ii, or iii * written informed consent exclusion criteria: * severe mental disorder * history of previous upper abdominal surgery (except laparoscopic cholecystectomy) * history of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection * exclude the early gastric cancer feasible for esd * enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging * history of other malignant disease within past five years * history of previous neoadjuvant chemotherapy or radiotherapy * history of unstable angina or myocardial infarction within past six months * history of cerebrovascular accident within past six months * history of continuous systematic administration of corticosteroids within one month * requirement of simultaneous surgery for other disease * emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * fev1\<50% of predicted values

Keywords: laparoscopic gastrectomy advanced gastric cancer elderly patients morbidity mortality